4-1BB agonism: adding the accelerator to cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 65, Issue 10, 2016, Pages 1243-1248

  Chester, Cariad ^a   Ambulkar, Siddhant ^a   Kohrt, Holbrook E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 1BB; Antibody dependent cell mediated cytotoxicity; Checkpoint inhibitors; CIMT 2015; Combination therapy; Immunotherapy

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; CHECKPOINT KINASE INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TNFRSF9 PROTEIN, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOLYSIS; HUMAN; IMMUNOMODULATION; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD137; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84962157662     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1829-2     Document Type: Review

References (38)

1. Kwon BS, Weissman SM (1989) cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86:1963–1967
2. Schoenbrunn A, Frentsch M, Kohler S, Keye J et al (2012) A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. J Immunol 189:5985–5994
3. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68
4. Vinay DS, Kwon BS (1998) Role of 4-1BB in immune responses. Semin Immunol 10:481–489
5. Vinay DS, Kwon BS (2011) 4-1BB signaling beyond T cells. Cell Mol Immunol 8:281–284
6. Anderson MW, Zhao S, Freud AG, Czerwinski DK et al (2012) CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol 181:795–803
7. Pang WL, Ho WT, Schwarz H (2013) Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance. Oncoimmunology 2:e23441
8. Wang C, Lin GHY, McPherson AJ, Watts TH (2009) Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 229:192–215
9. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169:4882–4888
10. Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH (2011) T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 244:197–217
11. Shuford WW, Klussman K, Tritchler DD, Loo DT et al (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:47–55
12. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L (1998) NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190:167–172
13. Kuang Y, Weng X, Liu X, Zhu H et al (2012) Effects of 4-1BB signaling on the biological function of murine dendritic cells. Oncol Lett 3:477–481
14. Melero I, Shuford WW, Newby SA, Aruffo A et al (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685
15. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH et al (2009) Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114:3431–3438
16. Gauttier V, Judor JP, Le Guen V, Cany J et al (2014) Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer 135:2857–2867
17. Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K (2007) Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 125:76–87
18. Curran MA, Geiger TL, Montalvo W, Kim M et al (2013) Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210:743–755
19. Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE (2003) Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res 63:2546–2552
20. Morales-Kastresana A, Catalán E, Hervás-Stubbs S, Palazón A et al (2013) Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. J Immunother Cancer 1:3
21. Chester C, Marabelle A, Houot R, Kohrt HE (2015) Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Curr Opin Immunol 33:1–8
22. Offringa R, Glennie MJ (2015) Development of next-generation immunomodulatory antibodies for cancer therapy through optimization of the IgG framework. Cancer Cell 28:273–275
23. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM (2015) NK Cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368
24. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA et al (2013) Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19:1858–1872
25. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K et al (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423–2432
26. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ et al (2012) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 122:1066–1075
27. Kohrt HE, Colevas AD, Houot R, Weiskopf K et al (2014) Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 124:2668–2682
28. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R et al (2014) A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. J Clin Oncol 32:5 (suppl; abstr 3007)
29. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37(5):508–516
30. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6:e19499
31. Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z (2012) Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol 2012:439235
32. Kocak E, Lute K, Chang X, May KF Jr et al (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 66:7276–7284
33. Xiao H, Huang B, Yuan Y, Li D et al (2007) Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13:1823–1830
34. Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y et al (2015) Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res 35:129–136
35. Chen F, Fan C, Gu X, Zhang H et al (2015) Construction of anti-CD20 single-chain antibody-CD28-CD137-TCRζ recombinant genetic modified T cells and its treatment effect on B cell lymphoma. Med Sci Monit 21:2110–2115
36. Duraiswamy J, Freeman GJ, Coukos G (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73:6900–6912
37. Bartkowiak T, Curran MA (2015) 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol 5:117
38. Ito F, Li Q, Shreiner AB, Okuyama R et al (2004) Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 64:8411–8419